Tesofensine for weight loss: separating trial data from TikTok hype

What did @brooke3287 actually say?

On day three of tesofensine, the creator dropped from 500 mcg to 250 mcg and reported feeling nothing. She noticed more effect at the higher dose on day one, described ongoing appetite and fatigue, and is now considering returning to 500 mcg. She also briefly discussed melanotane II causing new freckles and mentioned stacking multiple peptides including "motsie" (presumably MT-II or a similar compound) and BPC-157.

This is a first-person experience log, not a medical recommendation, and she frames it that way. She is watching other users' updates to calibrate her own experience, which is worth noting because that kind of social benchmarking can distort self-reported outcomes. If everyone in her feed says they felt something big on day one, she's primed to expect the same.

Does the science back this up?

Tesofensine's dose-dependent effects are well-documented, so her observation that 250 mcg felt weaker than 500 mcg is consistent with the clinical data. But "feeling nothing" at a lower dose on day three does not mean the drug isn't working.

The key trial here is Astrup et al. (2008, The Lancet), which tested 0.25 mg, 0.5 mg, and 1.0 mg tesofensine in 203 adults over 24 weeks. Weight loss was clearly dose-dependent: the 0.5 mg group lost roughly 11.3 kg versus 6.7 kg in the 0.25 mg group. However, appetite suppression and CNS effects like energy changes also scaled with dose, and side effects including elevated heart rate and blood pressure were more pronounced at higher doses. The creator's instinct that 0.25 mg felt blunted is pharmacologically plausible, but self-titrating upward based on three days of subjective data is not how this compound was studied or approved anywhere.

What did they get wrong (or right)?

She got the dose-response relationship directionally right. The science does show 500 mcg outperforms 250 mcg on appetite suppression. That part checks out.

What she got wrong, or at least left out entirely, is the cardiovascular risk profile. Tesofensine works primarily by inhibiting reuptake of serotonin, dopamine, and norepinephrine. That norepinephrine activity raises heart rate and blood pressure in a dose-dependent way. The Astrup 2008 trial reported mean heart rate increases of 7.4 bpm at 0.5 mg. A 2012 review by Lehr et al. in Obesity Reviews flagged this as the main reason tesofensine stalled in late-phase development. Stacking it with stimulant-adjacent compounds like MT-II (which also has cardiovascular and melanocortin effects) without mentioning this risk is a significant omission.

Her mention that melanotane II works better than melanotan I but causes more nausea is broadly consistent with pharmacology literature, so credit where it's due.

What should you actually know?

Tesofensine is not approved by the FDA or EMA. It exists in a regulatory gray zone and is typically obtained through compounding pharmacies or research chemical suppliers, with no standardized purity or dosing verification. That matters a lot when someone is self-titrating between doses based on how they feel on day three.

The compound does have real clinical data behind it, more than most peptides circulating on TikTok right now. But the Astrup trial was conducted under controlled conditions with monitored cardiovascular endpoints. Anyone increasing their dose at home, especially while stacking other peptides, is operating without that safety net.

• Tesofensine is not approved for human use in the US or EU as of 2024.
• Dose escalation should be guided by a clinician, not by comparing TikTok updates.
• Stacking multiple CNS-active compounds without medical oversight carries real cardiovascular risk.
• Three days is not enough time to evaluate efficacy for any weight-loss compound.

The peptide stack concern

The creator mentions taking tesofensine alongside what sounds like MT-II and BPC-157, and she hints at more peptides coming. Each of these compounds has its own mechanism and side effect profile. Melanocortin receptor agonists like MT-II can raise blood pressure and cause nausea. Combining them with a triple monoamine reuptake inhibitor like tesofensine is not a combination that has been studied in any clinical trial. There is no safety data for this stack. That is not a minor caveat. It is the whole ballgame for harm reduction.